Phosphorylated Tau 217 (p-tau217)

Phosphorylated Tau 217 (p-tau217)

> CSF and plasma p-tau217 as next-generation AD biomarker with superior accuracy, clinical validation, and comparison with p-tau181

Overview

Phosphorylated tau at threonine 217 (p-tau217) has emerged as the most accurate blood-based biomarker for Alzheimer's disease, surpassing p-tau181 in sensitivity, specificity, and ability to detect early pathology[@palmqvist_pta217]. First demonstrated in 2020 in both plasma and CSF, p-tau217 rapidly transitioned from discovery to clinical implementation, with the Lumipulse G p-tau217 assay receiving FDA breakthrough device designation and commercial availability through Mayo Clinic Laboratories[@mattson_pta217].

The p-tau217 epitope is highly specific for AD-type tau pathology, showing minimal elevation in other primary tauopathies such as progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD), making it valuable for differential diagnosis. Its exceptional performance in plasma enables non-invasive biomarker assessment that was previously only achievable through CSF collection or expensive PET imaging[@blennow_pta217].

Biochemistry and Pathophysiology

Tau Phosphorylation at Threonine 217

Threonine 217 is located in the proline-rich region of tau, adjacent to known phosphorylation sites (T212, T214). The p-tau217 epitope is generated by specific kinases including GSK3-beta and CDK5, which are activated in the AD brain[@karikari_pta217].

Phosphorylated Tau 217 (p-tau217)

> CSF and plasma p-tau217 as next-generation AD biomarker with superior accuracy, clinical validation, and comparison with p-tau181

Overview

Phosphorylated tau at threonine 217 (p-tau217) has emerged as the most accurate blood-based biomarker for Alzheimer's disease, surpassing p-tau181 in sensitivity, specificity, and ability to detect early pathology[@palmqvist_pta217]. First demonstrated in 2020 in both plasma and CSF, p-tau217 rapidly transitioned from discovery to clinical implementation, with the Lumipulse G p-tau217 assay receiving FDA breakthrough device designation and commercial availability through Mayo Clinic Laboratories[@mattson_pta217].

The p-tau217 epitope is highly specific for AD-type tau pathology, showing minimal elevation in other primary tauopathies such as progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD), making it valuable for differential diagnosis. Its exceptional performance in plasma enables non-invasive biomarker assessment that was previously only achievable through CSF collection or expensive PET imaging[@blennow_pta217].

Biochemistry and Pathophysiology

Tau Phosphorylation at Threonine 217

Threonine 217 is located in the proline-rich region of tau, adjacent to known phosphorylation sites (T212, T214). The p-tau217 epitope is generated by specific kinases including GSK3-beta and CDK5, which are activated in the AD brain[@karikari_pta217].

Key features of p-tau217:

• Appears early in the disease process, before widespread neurofibrillary tangle formation
• Highly sensitive to AD-type tau pathology specifically
• Correlates strongly with amyloid-beta deposition via unclear upstream mechanisms
• Shows minimal cross-reactivity with 4R tauopathies (PSP, CBD)
• Phosphorylation at T217 may promote tau aggregation by disrupting microtubule binding

Molecular Mechanisms

p-tau217 elevation occurs through similar mechanisms to other p-tau species[@cullen_pta217]:

The tight coupling between amyloid-beta pathology and p-tau217 elevation suggests that Aβ pathology drives tau phosphorylation at T217 through kinase activation and phosphatase inhibition, potentially as a trans-synaptic effect from amyloid-affected circuits.

Analytical Methods

Plasma p-tau217 Assays

The development of robust plasma p-tau217 immunoassays has driven clinical adoption[@blennow_pta217]:

Roche Elecsys p-tau217 (phospho-Tau Thr217) — Electrochemiluminescence immunoassay on cobas platforms, widely available in clinical labs.

Lumipulse G p-tau217 — Fujirebio automated chemiluminescence platform, FDA breakthrough device designation, available at Mayo Clinic Laboratories as a clinical test.

Simoa p-tau217 — Quanterix digital immunoassay with superior sensitivity, research use primarily.

Janssen p-tau217 — High-sensitivity prototype used in seminal 2020 discovery paper, now adapted to commercial platforms.

CSF p-tau217

CSF p-tau217 provides optimal performance with[@janelidze_pta217]:

• Higher concentrations than plasma
• No peripheral contribution
• Excellent correlation with plasma values (r > 0.90)
• Superior precision at lower concentrations

Performance Comparison

| Parameter | Plasma p-tau217 | CSF p-tau217 | Plasma p-tau181 |
|-----------|-----------------|---------------|-----------------|
| AUC (AD vs CN) | 0.94-0.97 | 0.95-0.98 | 0.89-0.92 |
| Sensitivity | 93-97% | 94-98% | 85-89% |
| Specificity | 88-93% | 90-95% | 81-86% |
| Availability | Growing | Widely available | Widely available |
| Cost | Moderate | Higher | Lower |

Clinical Validation

Diagnostic Performance

p-tau217 demonstrates the highest performance of any blood-based AD biomarker[@palmqvist_pta217]:

In primary care populations[@stom_lund_pta217]:

• AUC 0.94 for distinguishing AD from controls
• Outperforms memory testing in early detection
• High negative predictive value (98%) for ruling out AD

• AUC 0.97 in tertiary memory clinic cohorts
• Excellent performance across AD clinical stages (MCI to dementia)
• Robust in atypical presentations (non-amnestic, young-onset)

• High accuracy in community-based cohorts
• Elevated up to 15-20 years before symptom onset in familial AD
• Feasible for large-scale screening programs

Cutoff Values

Plasma p-tau217 (Elecsys/Lumipulse):
| Concentration | Interpretation | Clinical Context |
|--------------|----------------|-----------------|
| <0.5 pg/mL | Normal | Cognitively unimpaired |
| 0.5-1.2 pg/mL | Borderline | Requires clinical correlation |
| >1.2 pg/mL | Elevated | Consistent with AD pathology |

CSF p-tau217:
| Concentration | Interpretation | Clinical Context |
|--------------|----------------|-----------------|
| <25 pg/mL | Normal | Cognitively unimpaired |
| 25-40 pg/mL | Borderline | Requires clinical correlation |
| >40 pg/mL | Elevated | Consistent with AD pathology |

Age and APOE4-adjusted cutoffs improve accuracy in elderly populations[@ashford_pta217].

Comparison with p-tau181

p-tau217 outperforms p-tau181 in several key dimensions[@janelidze_pta217]:

| Feature | p-tau217 | p-tau181 |
|---------|----------|----------|
| AD sensitivity | 96% | 91% |
| AD specificity | 91% | 83% |
| Preclinical detection | Superior | Good |
| Non-AD tauopathy specificity | Higher | Lower |
| Plasma performance | AUC 0.96 | AUC 0.91 |
| Cost | Higher | Lower |
| Availability | Growing | Widely available |

Key advantages of p-tau217[@theron_pta217]:

• Better detection of non-amnestic AD variants (PCA, LPA)
• More specific for AD-type pathology
• Earlier detection in amyloid-positive individuals
• Better discrimination from PSP, CBD, FTD

Clinical Applications

Early Detection

p-tau217 excels in preclinical AD detection[@cullen_pta217]:

• Asymptomatic at-risk: Elevated in cognitively normal with amyloid PET positivity
• Dominantly inherited AD: Rises 10-20 years before expected onset
• Sporadic late-onset AD: Detects in prodromal MCI with >90% accuracy
• Primary care screening: Feasible for first-line biomarker evaluation

Differential Diagnosis

p-tau217 provides superior differentiation from non-AD dementias[@silva_pta217]:

| Condition | p-tau217 | p-tau181 | Notes |
|-----------|----------|----------|-------|
| Alzheimer's disease | Elevated | Elevated | Confirmed AD |
| DLB (with AD co-pathology) | Elevated | Elevated | High AD co-pathology |
| DLB (pure) | Normal | Normal | Differentiates from AD |
| PSP | Normal/Low | Normal | Excellent specificity |
| CBD | Normal/Low | Normal | Excellent specificity |
| FTD (non-AD) | Normal | Normal | Differentiates FTD-AD |
| Vascular dementia | Normal | Normal | Rules out AD |
| Normal pressure hydrocephalus | Normal | Normal | Rules out AD |

Disease Progression

p-tau217 tracks disease progression over time[@salvval_pta217]:

• Baseline level predicts future cognitive decline
• Annual change correlates with clinical deterioration
• Rate of increase distinguishes AD from stable MCI
• Helps stage disease severity within AD

Treatment Response

p-tau217 serves as pharmacodynamic marker for AD therapies[@cummings_pta217]:

• Anti-amyloid antibodies (lecanemab, donanemab): p-tau217 reduction correlates with amyloid removal
• Anti-tau therapies: Direct target engagement measurable
• Combination approaches: Biomarker evidence of multi-target effects

AT(N) Framework Integration

p-tau217 serves as the preferred T (Tau) biomarker in the AT(N) classification[@blennow_pta217]:

Optimal biomarker combinations:

• A (Amyloid): [GFAP](/biomarkers/gfap) or Aβ42/40 — screening
• T (Tau): p-tau217 — confirmation
• (N) (Neurodegeneration): [NfL](/biomarkers/neurofilament-light) — staging

• p-tau217 + [GFAP](/biomarkers/gfap) — blood-based, highly accurate
• p-tau217 alone — excellent but misses some cases

• [GFAP](/biomarkers/gfap) + p-tau217 + [NfL](/biomarkers/neurofilament-light)
• Covers amyloid, tau, and neurodegeneration axes
• Enables precise AD staging and differential diagnosis

Effect Modifiers

APOE Genotype

APOE4 carriers show higher p-tau217 levels and faster longitudinal increases[@ashford_pta217]:

• APOE4/4 carriers have 40-60% higher mean p-tau217
• Earlier elevation relative to amyloid PET
• Age-appropriate cutoffs needed for carrier populations

Age

p-tau217 shows modest age-related increases in cognitively normal elderly:

• Age-stratified cutoffs improve specificity in elderly populations
• Pre-senile AD (<65) shows strongest p-tau217 signal
• Very elderly (>85) require careful interpretation

Sex

Limited evidence suggests modest sex differences:

• No major performance differences in large cohorts
• Hormonal factors not well characterized

Non-AD Applications

Dementia with Lewy Bodies

p-tau217 helps distinguish DLB from AD[@silva_pta217]:

• Pure DLB without AD co-pathology shows normal p-tau217
• DLB with AD co-pathology shows elevated p-tau217
• Combined with alpha-synuclein biomarkers (CSF alpha-synuclein RT-QuIC) for DLB diagnosis

Primary Tauopathies

Minimal p-tau217 elevation in primary 4R tauopathies[@swieten_pta217]:

• PSP: Normal p-tau217 despite prominent tau pathology
• CBD: Normal p-tau217, distinguishes from AD
• Pick's disease (3R tau): Variable, often mildly elevated

Other Neurodegenerative Conditions

| Condition | p-tau217 | Comments |
|-----------|----------|----------|
| FTD-tau (Pick's) | Mildly elevated | Some AD co-pathology |
| FTD-TDP | Normal | Distinguishes from AD |
| CBS | Normal/Low | Distinguishes from AD |
| ALS | Normal | Unless ALS-AD |
| PD without dementia | Normal | Normal even in PD |

Future Directions

Point-of-Care Implementation

Blood p-tau217 enables widespread clinical use[@stom_lund_pta217]:

• Primary care screening for cognitive impairment
• Population-based screening programs
• Remote monitoring in clinical trials
• Point-of-care rapid testing (emerging technologies)

Combination Approaches

Optimal biomarker combinations[@cummings_pta217]:

• p-tau217 + GFAP: Best blood-based dual-marker panel
• p-tau217 + NfL: Adds neurodegeneration staging
• p-tau217 + p-tau181: Dual tau approach (less common)

Standardization

International efforts to harmonize p-tau217[@blennow_pta217]:

• Reference measurement procedure development
• Certified reference materials
• External quality assessment programs
• Cross-platform harmonization

Summary

p-tau217 is the most accurate blood-based biomarker for Alzheimer's disease currently available, offering superior performance to p-tau181 across virtually all metrics. Key points:

• Biochemistry: Phosphorylation at threonine 217 on tau, generated by GSK3-beta and CDK5
• Clinical performance: AUC 0.94-0.97 for AD diagnosis; 93-97% sensitivity, 88-93% specificity
• Cutoff values: Plasma >1.2 pg/mL or CSF >40 pg/mL indicates elevated AD-type tau
• Clinical utility: Early detection, differential diagnosis (PSP, CBD, FTD), disease monitoring, treatment response
• Strengths: Best-in-class accuracy, blood-based, specific for AD-type tau
• Limitations: Higher cost, less availability than p-tau181, requires continued standardization

Related Biomarkers

• [Phosphorylated Tau 181 (p-tau181)](/biomarkers/csf-pta181) — Widely available tau biomarker; slightly less accurate
• [Glial Fibrillary Acidic Protein (GFAP)](/biomarkers/gfap) — Astrocyte activation marker; combined with p-tau217 for AD screening
• [Neurofilament Light Chain (NfL)](/biomarkers/neurofilament-light) — Non-specific neurodegeneration marker
• [Total Tau (t-tau)](/biomarkers/total-tau) — Non-phosphorylated tau marker
• [Amyloid-beta 42/40 Ratio](/biomarkers/ab42-ratio) — Core amyloid biomarker

References